Search

Premise: Two distinct types of fossil infructescences from the early Eocene Laguna del Hunco flora, Chubut Province, Patagonia, Argentina, preserve features of the family Cunoniaceae. The goal of the study was to assess their affinities within Cunoniaceae and to interpret their evolutionary and biogeographical significance. Methods: Specimens were collected from the Tufolitas Laguna del Hunco, Huitrera Formation. They were prepared, photographed, and compared morphologically with similar extant and fossil fruits and infructescences using published literature and herbarium material. Results: The fruit and infructescence morphology place the fossil taxa within Cunoniaceae. They do not conform to any extant genus, supporting the erection of two new fossil genera. Racemofructus gen. nov. shares diagnostic features of the tribe Cunonieae, especially Weinmannia s.l., and exhibits two tribal morphological synapomorphies: a racemose inflorescence and a replum composed of a single column. Cunoniocarpa gen. nov. specimens are paniculate inflorescences with basipetally dehiscent, bicarpellate capsules that have persistent styles and calyces. Its replum morphology suggests an affinity to the tribe Caldcluvieae, particularly to the genus Ackama. Conclusions: The new Patagonian fossils described herein constitute the oldest record of cunoniaceous capsules globally, supplementing a significant body of fossil evidence from pollen, wood, and reproductive structures from southern South America and Antarctica that suggests that the Cunoniaceae were diversified and widely distributed in the southern hemisphere by the early Eocene. Racemofructus and Cunoniocarpa are, respectively, the first fossil records from South America of reproductive structures with affinity to tribes Cunonieae and Caldcluvieae. [ABSTRACT FROM AUTHOR]

Background: Cyclosporin is a calcineurin inhibitor widely used in renal transplant patients to prevent organ rejection. Several position papers have been published but no reports on the practical experience in pediatric patients undergoing conversion between cyclosporin innovator and generic products are available., Objective: To evaluate the pharmacokinetics and safety as part of therapeutic monitoring of cyclosporin in renal transplant pediatric patients who switch from the innovator to the generic formulation in Argentina., Setting: Hospital de Pediatría JP Garrahan, Buenos Aires, Argentina., Methods: Stable pediatric renal transplant patients (6 months post-transplant) switched from the innovator to the generic formulation of cyclosporin microemulsion capsule. Cyclosporin pharmacokinetic parameters were obtained while taking the innovator and after starting with the generic formulation. Blood samples were drawn before and 1, 2, and 3 h after drug administration and subsequently quantified. Pharmacokinetic parameters were obtained by means of a Bayesian approach., Main Outcomes Measure: Cyclosporin pharmacokinetic parameters (area under the curve, AUC; Blood concentration after 2 h, C2), adverse events and graft rejection., Results: A total of 12 patients were included. Median (range) age and time post-transplant were 10.7 years (6.5-17.7) and 8.3 years (3.4-14.0), respectively. Two patients or their parents did not consent to the switch. Median (range) dose normalized cyclosporin AUC and C2 were 1.15 (mg*h/L)/mg/kg (0.72-3.0) and 265.5 (ng/ml)/mg/kg (120.8-725.7), respectively, on the innovator therapy and 1.05 (mg*h/L)/mg/kg (0.54-2.22) and 317.1 (ng/ml)/mg/kg (116.7-564.7) for the generic drug after the switch. The median (range) percentage of change in the AUC and C2 when switching between formulations were 16.7 % (0.7-56.7) and 13.1 % (3.7-68.6), respectively. No significant changes in serum creatinine levels were registered when comparing before and after substitution of products. Adverse events (number of events) recorded 5 months before and after the switch included hirsutism (2), hypertension (2), and gingival hyperplasia (1)., Conclusion: Conversion of cyclosporin from innovator brand to generic in pediatric renal transplant patients needs to be closely monitored.